Glucagon-like peptide-2 vs Larazotide
Head-to-head comparison of Glucagon-like peptide-2 (Glucagon-like peptide-2) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Glucagon-like peptide-2 | Larazotide |
|---|---|---|
| Category | Gastrointestinal | Gastrointestinal |
| Full Name | Glucagon-like peptide-2 | Larazotide acetate (AT-1001) |
| Molecular Weight | ~3.7 kDa | N/A |
| Half-Life | ~7 min | short; designed for local gut action |
| Amino Acids | 33 | 8 |
| Typical Dose | Research-only dosing varies; native peptide is not routinely used clinically | 0.5-4 mg TID (clinical studies) |
| Route | SC|IV | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 90 | 40 |
| Research Status | Endogenous | Clinical |
Glucagon-like peptide-2 Benefits
- ✓mucosal trophic support
- ✓intestinal barrier repair
- ✓nutrient absorption support
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Glucagon-like peptide-2 Dosing
0.5–2 mg/day (research)|SC/IV
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Glucagon-like peptide-2 Side Effects
- ⚠nausea
- ⚠abdominal fullness
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
Glucagon-like peptide-2
Native GLP-2 is a key enteric growth factor with rapid degradation by DPP-4. Its therapeutic value is best known through GLP-2 analog development, but the native peptide itself is a real GI-relevant hormone.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.